Skip to main content
SpringerLink
Log in

Cost effectiveness of new therapies for advanced melanoma . . . a matter of perspective?

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Canadian dollars

  2. The studies were funded by Merck.

  3. The study was funded by Bristol-Myers Squibb.

  4. The study was funded by Bristol-Myers Squibb.

References

  1. Wang J, et al. Cost-Effectiveness of Pembrolizumab (Keytruda(R)) Versus Ipilimumab in Patients with Advanced Melanoma in Canada. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN112, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44450

  2. Wang J, et al. Cost Effectiveness of Pembrolizumab (Keytruda(R)) Versus Ipilimumab in Patients with Advanced Melanoma in the United States. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN114, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44776

  3. Lu T, et al. Cost Effectiveness of Pembrolizumab and Ipilimumab in Advanced Melanoma. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN86, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44556

  4. Potluri R, et al. Health Care Cost Comparison Analysis of Nivolumab + Ipilimumab Regimen and Nivolumab Monotherapy Versus Established Advanced Melanoma Therapies Utilizing Clinical Trial and Real-World Data. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN60, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44522

  5. Potluri R, et al. Health Care Cost Comparison Analysis of Nivolumab + Ipilimumab Regimen, Nivolumab Monotherapy, and Ipilimumab Monotherapy Utilizing Clinical Trial Data: a European Perspective. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN58, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44479

  6. Tran DM, et al. Cost Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared to Monotherapy for Metastatic Melanoma from a Us Societal Perspective. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS12, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44803

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost effectiveness of new therapies for advanced melanoma . . . a matter of perspective?. PharmacoEcon Outcomes News 755, 17–18 (2016). https://doi.org/10.1007/s40274-016-3124-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3124-z

Search

Navigation